<p>MaxCyte, Inc. (LON:MXCT - 获取免费报告) 的股价在周四创下 52 周新低。该股最低交易价为 200 便士（$2.60），最后交易价为 205.68 便士（$2.67），成交量为 26796 股。该股此前收盘价为 213 便士（$2.77）。</p>
<h2>MaxCyte 股价下跌 3.4%</h2>
<p>该公司的流动比率为 9.81，速动比率为 14.38，债务与股本比率为 8.59。该公司的市值为 2.7151 亿英镑，市盈率为-7.54，贝塔值为 1.13。该公司的 50 日移动平均价格为 294.19 便士，200 日移动平均价格为 302.57 便士。</p>
<h2>关于 MaxCyte</h2>
<p>(获取免费报告)</p>
<p>MaxCyte 是一家领先的细胞工程公司，提供支持平台技术，以推动下一代基于细胞的治疗的发现、开发和商业化，并支持创新的基于细胞的研究。MaxCyte 提供一流的技术，并配备持续的支持，旨在促进各种细胞和载荷的复杂工程，旨在为患者提供新的治疗选择。</p>
<h2>推荐故事</h2>
<ul>
<li>五只我们更看好的股票超过 MaxCyte</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>RH 股价下跌近 40%：投资者现在可以转向哪里</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>关税、分拆和 R2 更新是 Rivian 的积极信号</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>Cathie Wood 大量购买百度——现在是购买的合适时机吗？</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 MaxCyte 吗？</h2>
<p>在考虑 MaxCyte 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MaxCyte 并不在名单上。</p>
<p>虽然 MaxCyte 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MXCT

<p>MaxCyte (LON:MXCT) 的股价创下 52 周新低，报 GBX 200（$2.60），收盘价为 GBX 205.68（$2.67），下跌 3.4%。该公司的市值为 2.7151 亿英镑，市盈率为-7.54，流动比率为 9.81。分析师目前对该股票的评级为持有，但建议有更好的投资选择。MaxCyte 专注于细胞工程技术，用于细胞治疗和研究</p>

<p>MaxCyte, Inc. (LON:MXCT - Get Free Report)'s share price hit a new 52-week low on Thursday . The stock traded as low as GBX 200 ($2.60) and last traded at GBX 205.68 ($2.67), with a volume of 26796 shares. The stock had previously closed at GBX 213 ($2.77).</p>
<div class="lb-trans"><p>MaxCyte, Inc. (LON:MXCT - 获取免费报告) 的股价在周四创下 52 周新低。该股最低交易价为 200 便士（$2.60），最后交易价为 205.68 便士（$2.67），成交量为 26796 股。该股此前收盘价为 213 便士（$2.77）。</p>
</div><h2>MaxCyte Trading Down 3.4 %</h2>
<div class="lb-trans"><h2>MaxCyte 股价下跌 3.4%</h2>
</div><p>The company has a current ratio of 9.81, a quick ratio of 14.38 and a debt-to-equity ratio of 8.59. The firm has a market capitalization of £271.51 million, a price-to-earnings ratio of -7.54 and a beta of 1.13. The company has a fifty day moving average price of GBX 294.19 and a two-hundred day moving average price of GBX 302.57.</p>
<div class="lb-trans"><p>该公司的流动比率为 9.81，速动比率为 14.38，债务与股本比率为 8.59。该公司的市值为 2.7151 亿英镑，市盈率为-7.54，贝塔值为 1.13。该公司的 50 日移动平均价格为 294.19 便士，200 日移动平均价格为 302.57 便士。</p>
</div><h2>About MaxCyte</h2>
<div class="lb-trans"><h2>关于 MaxCyte</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>MaxCyte is a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research. MaxCyte brings best-in-class technology paired with ongoing support designed to facilitate complex engineering of a wide variety of cells and payloads, with the aim of advancing new treatment options for patients.</p>
<div class="lb-trans"><p>MaxCyte 是一家领先的细胞工程公司，提供支持平台技术，以推动下一代基于细胞的治疗的发现、开发和商业化，并支持创新的基于细胞的研究。MaxCyte 提供一流的技术，并配备持续的支持，旨在促进各种细胞和载荷的复杂工程，旨在为患者提供新的治疗选择。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than MaxCyte</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Shares of RH Down Nearly 40%: Where Investors Can Turn To Now</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Tariffs, Spin-Out, and R2 Updates Are Positive Signs for Rivian</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 MaxCyte</li>
<li>现在购买的 3 只沃伦·巴菲特股票</li>
<li>RH 股价下跌近 40%：投资者现在可以转向哪里</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>关税、分拆和 R2 更新是 Rivian 的积极信号</li>
<li>三只值得购买和持有的医疗保健分红股票</li>
<li>Cathie Wood 大量购买百度——现在是购买的合适时机吗？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MaxCyte 吗？</h2>
</div><p>Before you consider MaxCyte, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 MaxCyte 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MaxCyte 并不在名单上。</p>
</div><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MaxCyte 目前在分析师中被评为持有，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

MaxCyte (LON:MXCT) 创下 52 周新低 - 你是否应该卖出？